Immunochemical-based assays in the bioanalysis of immunoglobulins

被引:9
作者
Lamari, F
Anastassiou, ED
Dimitracopoulos, G
Karamanos, NK [1 ]
机构
[1] Univ Patras, Dept Chem, Sect Organ Chem Biochem & Nat Prod, GR-26110 Patras, Greece
[2] Univ Patras, Sch Med, Dept Microbiol, GR-26110 Patras, Greece
关键词
enzyme immunoassay; intravenous immunoglobulin; specific antibodies; primary immunodeficiency; neonatal infection; bacterial antigens;
D O I
10.1016/S0731-7085(00)00405-2
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Intravenous immunoglobulin (IVIG) preparations consist of IgG derived from a pool of human plasma of healthy individuals and have been used as routine treatment of patients with primary and secondary immunodeficiencies, autoimmune, and/or inflammatory diseases. Emergence of new infectious agents and development of antibiotic resistance in many bacteria have posed serious problems in the treatment of infections. Since IVIGs contain natural antibodies that occur in the healthy population, their administration to immunocompromised hosts either as a prophylactic agent or as complementary treatment to the usual antimicrobial treatment have been studied. Contradictory results obtained by several clinical studies in respect to the clinical efficacy of IVIGs have in part been ascribed to the poor characterization of IVIG preparations in terms of their specific antibody content against the various pathogenic microorganisms. Immunoassays constitute a promising tool for bioanalysis of IVIGs thanks to the high sensitivity, repeatability and ease of implementation. Ensuring high selectivity, enzyme immunoassays have been used for determination of the levels of pathogen-specific antibodies in IVIG preparations. In this review, the application of irnmunoassays monitoring such specific antibodies in IVIGs and the relationship of estimated titers with their in vitro opsonic activity are summarized. The relationship of the content of specific antibodies in IVIGs and their functional efficacy with the outcome of clinical studies including patients with primary immunodeficiencies and premature neonates treated with IVIGs is also discussed. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:939 / 946
页数:8
相关论文
共 34 条
[21]   PROTECTIVE EFFECT AND ANTIBODY TITER OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) AGAINST CLINICAL ISOLATES OF OPPORTUNISTIC BACTERIA [J].
NAKAE, T ;
NAKAJIMA, T ;
NAGAI, H ;
WATANABE, M ;
YOKOYAMA, K .
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 1994, 114 (12) :972-979
[22]   Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: Implications for therapeutic efficacy [J].
Norrby-Teglund, A ;
Basma, H ;
Andersson, J ;
McGeer, A ;
Low, DE ;
Koth, M .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (03) :631-638
[23]  
NorrbyTeglund A, 1996, J IMMUNOL, V156, P3057
[24]   Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G [J].
NorrbyTeglund, A ;
Kaul, R ;
Low, DE ;
McGeer, A ;
Andersson, J ;
Andersson, U ;
Kotb, M .
INFECTION AND IMMUNITY, 1996, 64 (12) :5395-5398
[25]   INTRAVENOUS IMMUNE GLOBULINS - A REVIEW OF THEIR USES IN SELECTED IMMUNODEFICIENCY AND AUTOIMMUNE-DISEASES [J].
PIROFSKY, B ;
KINZEY, DM .
DRUGS, 1992, 43 (01) :6-14
[26]   Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia:: A retrospective survey of 31 patients [J].
Quartier, P ;
Debré, M ;
De Blic, J ;
de Sauverzac, R ;
Sayegh, N ;
Jabado, N ;
Haddad, E ;
Blanche, S ;
Casanova, JL ;
Smith, CIE ;
Le Deist, F ;
de Saint Basille, G ;
Fischer, A .
JOURNAL OF PEDIATRICS, 1999, 134 (05) :589-596
[27]   Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells [J].
RomeroSteiner, S ;
Libutti, D ;
Pais, LB ;
Dykes, J ;
Anderson, P ;
Whitin, JC ;
Keyserling, HL ;
Carlone, GM .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1997, 4 (04) :415-422
[28]   Intravenous immunoglobulin therapy for severe Clostridium difficile colitis [J].
Salcedo, J ;
Keates, S ;
Pothoulakis, C ;
Warny, M ;
Castagliuolo, I ;
LaMont, JT ;
Kelly, CP .
GUT, 1997, 41 (03) :366-370
[29]   Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93 [J].
Skull, S ;
Kemp, A .
ARCHIVES OF DISEASE IN CHILDHOOD, 1996, 74 (06) :527-530
[30]   Human intravenous immunoglobulin in primary and secondary antibody deficiencies [J].
Stiehm, ER .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1997, 16 (07) :696-707